by winston » Fri Jul 10, 2026 10:57 am
Wall Street analysts expect Eli Lilly's new oral weight-loss pill, Foundayo (orforglipron), to generate between $1.5 billion and $2.8 billion in 2026 sales.
The consensus target sits near $1.6 billion.
The drug received FDA approval to treat obesity in April 2026.
It's all about "how much you made when you were right" & "how little you lost when you were wrong"